Levine Media Group

29/10/2025

John Hoekman, co-founder and CEO of Junevity, discusses the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform for identifying dysregulated transcription factors, and its lead programs targeting type 2 diabetes and obesity.

https://thebioreport.podbean.com/e/hitting-the-reset-button-on-cellular-aging/

24/10/2025

Philippa Ward discusses her journey as the mother of a child diagnosed with tuberous sclerosis complex, the challenges posed by the condition’s complexities, and how she found both a community of support and her own voice as an advocate. Global Genes

Philippa Ward discusses her journey as the mother of a child diagnosed with tuberous sclerosis complex, the challenges posed by the condition’s complexities, and how she found both a community of support and her own voice as an advocate.

23/10/2025

Aaron Cohen, Head of Research Oncology, Clinical Data at Flatiron Health, joins Amar Drawid, on Life Sciences DNA to explore how large language models are transforming oncology research.

Aaron Cohen, head of research oncology, clinical data for Flatiron Health, sits down with Amar Drawid to discuss Flatiron’s use of large language models to e...

22/10/2025

Stacy Lindborg, CEO of Imunon, discusses the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease.

https://thebioreport.podbean.com/e/changing-the-ovarian-cancer-treatment-landscape-with-a-dna-mediated-immunotherapy/

15/10/2025

Drew Endy, associate professor of bioengineering and senior fellow of the Hoover Institution, Stanford University, discusses China’s all-of-nation strategy, how the United States has misallocated research dollars, and why a cultural embrace of biotechnology will be critical for the success of either country.

10/10/2025

Kristin McKay, CEO of the Hunter syndrome patient advocacy organization Project Alive, discusses the need for new therapies, the importance of early detection, and the patient community’s concerns with regulatory delays in approving needed treatments. Global Genes

Kristin McKay, CEO of the Hunter syndrome patient advocacy organization Project Alive, about the need for new therapies, the importance of early detection, and the patient community’s concerns with regulatory delays in approving needed treatments.

08/10/2025

Arc Institute’s Core Investigator Hani Goodarzi, Ultima Genomics CEO Gilad Almogy, and 10x Genomics CEO Serge Saxonov discuss their collaboration on the ARC Virtual Cell Atlas, which uses high-throughput single-cell genomics, artificial intelligence, and open science to understand the complexities of cellular behavior. They talk about how it will serve academic and industry researchers developing therapies, help unravel disease mechanisms at a cellular level, and provide broad access to advanced cellular analytics.

https://thebioreport.podbean.com/e/transforming-drug-discovery-and-disease-research%e2%80%94one-cell-at-a-time/

03/10/2025

Amélie Lothe, global medical community head for rare epilepsies at UCB, discusses the importance of viewing developmental and epileptic encephalopathies as complex neurodevelopmental conditions, the need to go beyond seizure frequency when it comes to clinical trial outcome measures, and what drug developers can do to improve their research focus to include broader patient and caregiver experiences. Global Genes

Amelie Lothe, global medical community head for rare epilepsies at UCB, about the importance of viewing developmental and epileptic encephalopathies as complex neurodevelopmental conditions, the need to go beyond seizure frequency when it comes to clinical trial outcome measures, and what drug devel...

30/09/2025

Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.

Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. The Bio Report A Dual Action Approach to Treating MASH MASH, a chronic and progressive form of fatty liver disease that until recently was known as NASH, affects millions of people in the Un

26/09/2025

Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental once-daily, oral medicine for achondroplasia; what’s known about it from studies conducted to date, and why he believes it will offer competitive advantages over existing therapies. Global Genes

Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental once-daily, oral medicine for achondroplasia; what’s known about it from studies conducted to date, and why he believes it will offer competitive advantages over existing therapies.

25/09/2025

What happens when AI touches every role, every day, in clinical development? Stephen Pyke of Parexel, in conversation with Nagaraja Srivatsan, highlights why preparing teams early is essential to unlock their full potential.

trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s

19/09/2025

Paul Peter Tak, president and CEO of Candel Therapeutics, discusses the company's viral immunotherapy for brain cancer, how it works, and what clinical studies have shown to date. Global Genes

Paul Peter Tak, president and CEO of Candel Therapeutics, discsses its viral immunotherapy, how it works, and what clinical studies have shown to date.